Akcea submits NDA for volanesorsen

Akcea Therapeutics Inc. (NASDAQ:AKCA) submitted an NDA to FDA for volanesorsen (IONIS-APOCIIIRx) to treat familial chylomicronemia syndrome (FCS). Volanesorsen is an apolipoprotein C-III (APOCIII; APOC3) antisense inhibitor.

In March, Ionis Pharmaceuticals Inc. (NASDAQ:IONS) spun out Akcea to house its programs targeting lipid disorders. Ionis owns approximately 70.8% of Akcea's shares (see BioCentury Extra, March 27)...